Forte Biosciences (FBRX) Other Non Operating Income (2018 - 2026)
Forte Biosciences' (FBRX) quarterly Other Non Operating Income came in at $676000.0 in Q1 2026, up 44.44% year-on-year from $468000.0 in Q1 2025, and up 150.71% on a QoQ basis from -$1.3 million in Q4 2025.
Forte Biosciences (FBRX) Other Non Operating Income (2018 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 9 years of Other Non Operating Income data on file, last reported at $676000.0 in Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 44.44% year-over-year to $676000.0 in Q1 2026; TTM through Mar 2026 was $374000.0, a 452.83% increase from a year earlier, with the FY2025 full-year figure at $166000.0, up 187.37% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $676000.0, up from -$1.3 million in the prior quarter.
- Over the last five years, Other Non Operating Income for FBRX reached as high as $701000.0 in Q3 2025 and fell as low as -$1.3 million in Q4 2025.
- Historically, Other Non Operating Income has averaged $23117.6 across 5 years, with a median of $138000.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 1034.78% in 2023 and fell as far as 515.0% in 2023.
- Year by year, Other Non Operating Income stood at -$100000.0 in 2022, then plunged by 515.0% to -$615000.0 in 2023, then tumbled by 81.79% to -$1.1 million in 2024, then fell by 19.23% to -$1.3 million in 2025, then jumped by 150.71% to $676000.0 in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were $676000.0 in Q1 2026, -$1.3 million in Q4 2025, and $701000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 676,000.00 |
| Dec 31, 2025 | -1.33 Mn |
| Sep 30, 2025 | 701,000.00 |
| Jun 30, 2025 | 330,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 307,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | -615,000.00 |
| Sep 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 138,000.00 |
| Mar 31, 2023 | 102,000.00 |
| Dec 31, 2022 | -100,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Dec 31, 2021 | -42,000.00 |
| Sep 30, 2021 | -52,000.00 |
| Jun 30, 2021 | -65,000.00 |